surements were performed in a random order using a mercury sphygmomanometer by two of the investigators (KK, AK). The mean of two measurements in the sitting position was used.
Both ABPM and office measurements were used by 518 practicing clinicians to assess the antihypertensive efficacy of telmisartan in 1,628 patients, 940 untreated and 675 previously on other drugs. After baseline ABPM, patients were started on (or switched to) telmisartan 40 mg qd, which was increased to 80 mg qd (unless patients were hypotensive) after 2 weeks; if office BP was Ͼ 140/85 mmHg after 4 further weeks, telmisartan 80 mg/hydrochlorothiazide 12.5 mg was given for a final 4 weeks. ABPM was performed at completion of treatment using an intention-to-treat analysis. Of the 1,628 patients, 1,557 (95%) successfully completed both ABPM procedures. Baseline BP by 24 h ABPM was 135/77 mmHg, and it fell by 10.7/6.5 mmHg with telmisartan or telmisartan-HCT (12.5/8.0 mmHg in previously untreated patients, 8.1/ 4.3 mmHg in switched patients). All changes were highly significant. BP fell by 10.0/6.2 mmHg during the final 6 h of the dosing interval, and by 11.5/7.0 in the 4 h after awakening, demonstrating substantial sustained efficacy during these important periods. The office baseline was 150/91 mmHg with a mean fall of 20/12 mmHg (22.8/13.3 mmHg in untreated and 16.6/9.2 mmHg in switched patients), indicating, when compared with ABPM, considerable white coat and regression-to-the-mean effects in this community-based trial. BP was controlled (Ͻ 140/90 mmHg) in 90% of previously untreated and 84% of switched patients by ABPM; and, respectively, 84% and 71% by office readings. In conclusion, this study demonstrates the feasibility of ABPM in clinical practice and highlights major differences between ABPM and conventional BP measurements. Telmisartan-based treatment was highly effective in achieving BP control, including a majority of patients previously on other therapies. Purpose: To determine if the Omron HEM637 wrist model with the wrist positioning sensor turned on (Son) is more accurate relative to upper arm auscultation by trained professions than when the sensor was manually turned off (Soff).
Method: Forty-four subjects, at least 30 years old, had repeated, sequential dual-observer upper arm auscultatory measurements (5-6 each) and oscillometric Omron HEM637 wrist measurements (4 each). Nineteen subjects were assigned to the wrist sensor On group and 25 were assigned to the wrist sensor Off group. A total of 425 auscultatory and 164 wrist measurements were analyzed.
Result: The Omron HEM-637 measured the BP with equal accuracy to the observers using the auscultatory technique (difference Ϫ1.37Ϯ8.51 / 3.47Ϯ8.07mmHg, pϭ0.71/0.14). The wrist sensor did improve the accuracy of the measurements compared to the subjects that had the sensor deactivated. The sensor On group (Son) measured the SBP (Ϫ2.32Ϯ5.59 mmHg) and DBP (Ϫ2.56Ϯ5.36mmHg) statistically the same as by auscultation (pϭ0.60 for SBP and pϭ0.44 for DBP). The sensor Off (Soff) group measured the SBP (Ϫ3.03Ϯ7.12 mmHg) and DBP (Ϫ5.56Ϯ6.68mmHg) statistically different than auscultation (pϭ0.46 for SBP and pϭ0.02 for DBP). The higher (negative) measurement for both the SBP and DBP suggests that the average position of the wrist was 1.75 inches (4.4cm) below the heart level in this group with the sensor off.
Conclusion: This study demonstrated that the Omron HEM-637 monitor with a wrist sensor more accurately measured blood pressure compared to the same model with the sensor turned off, which was statistically different for DBP. Clinic blood pressure (CBP) measurement has been the standard for diagnosis and treatment of hypertension. Limitations of CBP such as observer bias, white coat and placebo effects have been identified. In recognition of these limitations, some physicians suggest that patients obtain BP readings outside of their office. The objective of this study is to compare home blood pressure (HBP) measurements with pharmacy
